🇨🇦 PF-06954522 IR (Formulation 1) in Canada

PF-06954522 IR (Formulation 1) (pf-06954522-ir-formulation-1) regulatory status in Canada.

Marketing authorisation

PF-06954522 IR (Formulation 1) in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is PF-06954522 IR (Formulation 1) approved in Canada?

Yes. Health Canada has authorised it.

Who is the marketing authorisation holder for PF-06954522 IR (Formulation 1) in Canada?

Pfizer Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.